Korro Bio, Inc.
KRRO Healthcare Biotechnology
Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024. In the quarter to June 2026, revenue fell 86.3%, EPS grew 61.0% and free cash flow grew 12.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KRRO
Korro Bio, Inc. (KRRO) Beneish M-score
Korro Bio, Inc.'s Beneish M-score for fiscal 2025 is −3.49; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −3.49 | (0.27) |
| FY2021 | −3.22 | (109.67) |
| FY2020 | 106.45 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.20 | — | 0.19 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.68 | — | 0.28 | |
| Sales growth index | 2.81 | — | 2.51 | |
| Depreciation index | 0.19 | — | 0.02 | |
| SG&A index | 0.33 | — | −0.06 | |
| Total accruals to total assets | (0.34) | — | −1.60 | |
| Leverage index | 1.59 | — | −0.52 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −3.49 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| KRRO Korro Bio, Inc. | −3.5× |
| CUE Cue Biopharma, Inc. compare | −0.4× |
| NKTX Nkarta, Inc. compare | — |
| ALXO ALX Oncology Holdings Inc. compare | — |
| AVXL Anavex Life Sciences Corp. compare | — |
| TLSA Tiziana Life Sciences Ltd compare | — |
| MOLN Molecular Partners AG Sponsored ADR compare | — |
| ANTX AN2 Therapeutics, Inc. compare | — |
| TARA Protara Therapeutics, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI